LENZ Therapeutics vs Scilex
LENZ and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LENZ and SCLX compare
LENZ Therapeutics is the larger company, worth 9.4 times as much as Scilex ($129M against $13.7M).
LENZ Therapeutics grew revenue faster over the last twelve months (330% versus −28.5% for Scilex).
LENZ Therapeutics keeps more of each dollar of sales as profit, with a net margin of −587% compared with −1470% at Scilex.
LENZ Therapeutics scores higher on the StockData Score (9 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LENZ | SCLX |
|---|---|---|
| Size and price | ||
| Market cap | $129M | $13.7M |
| Share price | $4.11 | $1.61 |
| Change, 1 year | −82.3% | −91.4% |
| Change, 5 years | −94.7% | −99.5% |
| Beta (5Y) | 1.08 | 0.82 |
| Employees | 152 | 34 |
| StockData Score | ||
| Total score | 9 (better) | 1 |
| Valuation score | 3 (better) | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 5 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 6.0× | 0.4× (better) |
| P/B | 0.6× | – |
| FCF yield | −88.6% | – |
| Fair value | $8.07 | – |
| Margin of safety | 49.0% | – |
| Growth | ||
| Revenue growth (TTM) | 330% (better) | −28.5% |
| Revenue growth, 5Y average | – | 5.1% |
| Profitability | ||
| Gross margin | – | 161% |
| Operating margin | −632% (better) | −1136% |
| Net margin | −587% (better) | −1470% |
| FCF margin | −533% | – |
| Return on equity | −59.2% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −22.2× |
| Current ratio | 13.55 (better) | 0.07 |
| Altman Z-score | 1.99 (better) | −12.74 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 110% | 9.8% |
| Held by insiders | 6.7% | – |
| Insider net buying, 12 months | −$8.8M (better) | −$12.8M |
| Short interest, % of float | 24.1% | – |
Go deeper
- LENZ stock overview
- LENZ income statement
- LENZ valuation and score
- SCLX stock overview
- SCLX income statement
- SCLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.